#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Tirzepatide vs semaglutide: indirect data
A 2026 analysis compared SURMOUNT-1 with STEP 1. Tirzepatide 10 mg and 15 mg were associated with greater weight reduction, but this was not a new trial.
TRIUMPH-2: Retatrutide at 80 Weeks
TRIUMPH-2 found greater weight loss with retatrutide than placebo at 80 weeks in adults with obesity and type 2 diabetes.
Semaglutide in Pediatric Craniopharyngioma
A 20-patient retrospective series links semaglutide with lower BMI in adolescents with craniopharyngioma-related obesity, but cannot prove causation.
Tirzepatide lean-mass review
A 2026 review found that tirzepatide weight loss mostly came from fat, but lean mass also fell and muscle function was not measured.
Tirzepatide and NAION: New Record
A new French journal record names tirzepatide and NAION, but its no-abstract PubMed entry cannot establish clinical details or causation.
New amylin agonists for obesity and T2D
Zenagamtide, eloralintide and CagriSema have early to late-stage results in obesity and type 2 diabetes. Their evidence is not interchangeable.
Incretin injections vs intensified insulin
A 2026 review found lower hypoglycaemia and weight with incretin-based injections versus intensified insulin, but the average HbA1c edge was small.
Semaglutide and taste in mice
A 2026 mouse study found preserved taste responses during chronic semaglutide treatment, despite changes in sucrose-directed behavior.
A two-timepoint semaglutide brain map
A mouse study mapped semaglutide-linked activity across more than 500 brain areas using two timepoints, finding 24 engaged regions.
Surgery vs semaglutide and tirzepatide
A 44,025-person record study associated bariatric surgery with more weight loss than semaglutide or tirzepatide, but it was not randomized.
Tirzepatide response after eight weeks
A SURMOUNT post hoc analysis linked early tirzepatide weight response with larger 72-week changes, while later responders still lost weight.
Adolescent GLP-1 use: what remains unknown
A 2026 commentary reviews skeletal, reproductive and psychosocial questions around semaglutide and other GLP-1 drugs in adolescents.